Roberto Pili

Roberto Pili

Auto-generated profile, based on publicly available information

Roberto Pili

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DQDavid Z. Qian
David Z. Qian
XWXiaofei Wang
Xiaofei Wang
SKSushant K. Kachhap
Sushant K. Kachhap
YKYukihiko Kato
Yukihiko Kato
YWYongfeng Wei
Yongfeng Wei
RPRoberto Pili
Roberto Pili
Chromatin remodeling agents such as histone deacetylase inhibitors have been shown to modulate gene expression in tumor cells and inhibit tumor growth and angiogenesis. Vascular endothelial growth factor (VEGF) and VEGF receptors represent critical molecular targets for antiangiogenesis therapy. In this study, we investigated the biological effect of the histone deacetylase inhibitor NVP-LAQ824 in combination with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 on tumor growth and angiogenesis. We report that treatment with NVP-LAQ824 affected tumor and endothelial cells and was associated with increased histone acetylation, p21 up-regulation, and growth inhibition. In addition, NVP-LAQ824 treatment inhibited the expression of angiogenesis-related genes such as angiopoietin-2, Tie-2, and survivin in endothelial cells and down-regulated hypoxia-inducible factor 1-α and VEGF expression in tumor cells. Combination treatment with NVP-LAQ824 and PTK787/ZK222584 was more effective than single agents in inhibiting in vitro and in vivo VEGF-induced angiogenesis. Endothelial cell proliferation, tube formation, and invasion into the Matrigel plugs were reduced. In mouse models with established subcutaneous prostate (PC3) and orthotopic breast tumors (MDA-MB321), this combination treatment induced 80 to 85% inhibition of tumor growth without overt toxicity. These results suggest that the combination of histone deacetylase inhibitors and VEGF receptor inhibitors may target multiple pathways in tumor progression and angiogenesis and represents a novel therapeutic approach in cancer treatment.

22 May 2007 in The Prostate
Verified
Journal Article
Closed access
PDF file
DQDavid Z. Qian
David Z. Qian
YWYong‐Feng Wei
Yong‐Feng Wei
XWXiaofei Wang
Xiaofei Wang
YKYukihiko Kato
Yukihiko Kato
LCLinzhao Cheng
Linzhao Cheng
RPRoberto Pili
Roberto Pili

1 May 2002
Verified
Journal Article
Closed access
SSSilvia M Sirchia
Silvia M Sirchia
MRMingqiang Ren
Mingqiang Ren
RPRoberto Pili
Roberto Pili
ESElena Sironi
Elena Sironi
GSGiulia Somenzi
Giulia Somenzi
NSNicoletta Sacchi
Nicoletta Sacchi

13 January 2005 in The Prostate
Verified
Journal Article
Closed access
PDF file
DQDavid Z. Qian
David Z. Qian
MRMingqiang Ren
Mingqiang Ren
YWYongfeng Wei
Yongfeng Wei
XWXiaofei Wang
Xiaofei Wang
FGFleur van de Geijn
Fleur van de Geijn
RPRoberto Pili
Roberto Pili

26 January 2007 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HVHenk Verheul
Henk Verheul
DQDavid Z. Qian
David Z. Qian
MCMichael A. Carducci
Michael A. Carducci
RPRoberto Pili
Roberto Pili